Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of both gender aged from 6 months to 6 years, who have been admitted to infectious diseases unit.~2. Diarrhea (watery diarrhea at least 3 times a day).~3. CDS score of ≥1.~4. The first 48 hours from the onset of the first diarrhea episode.~5. Start of study treatment (Ergoferon/Placebo) within 12 hours after the start of the standard hospital therapy.~6. Availability of a patient information sheet (Informed Consent form) signed by the patient's parents/adopters to confirm the child's participation in the clinical trial signed by one parent/adopter of the patient.~Exclusion Criteria:~1. Suspected bacterial intestinal infection.~2. Suspected infectious diseases affecting other organ systems (e.g. pneumonia, meningitis, sepsis, otitis media, urinary tract infection, etc.).~3. Severe intestinal infection.~4. Severe dehydration (CDS score ≥7).~5. Anuria (acute kidney injury).~6. Medical history or prior diagnosis of serious diseases, including primary/secondary immunodeficiency, oncological disease, diabetes mellitus, infantile cerebral palsy, mucoviscidosis/cystic fibrosis etc.~7. Exacerbation, or decompensation of chronic disease, including diseases of the digestive system that would affect the patient's ability to participate in the clinical trial.~8. Malabsorption syndrome, including congenital or acquired lactose intolerance/lactase deficiency or any other disaccharidase deficiency and galactosemia.~9. Allergy/ intolerance to any of the components of medications used in the treatment.~10. Course intake of medicines listed in the section Prohibited concomitant treatment for 2 weeks prior to the enrollment in the trial.~11. Participation in other clinical trials within 3 months prior to the enrollment in this study.~12. Patients whose parents/adopters, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the dosing regimen of the study drugs.~13. Patient's parents/adopters are related to the research staff of the clinical investigative site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.~14. The patient's parent/adopter works for MATERIA MEDICA HOLDING (i.e., is the company's employee, temporary contract worker or appointed official responsible for carrying out the research) or the immediate relative.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Ergoferon (Type: EXPERIMENTAL): Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
- Placebo (Type: PLACEBO_COMPARATOR): Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete